A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-16. Anything still debated is marked as such rather than presented as settled.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
In 1955, Harry Winokur worked with brother-in-law William Rosenberg, the founder of Dunkin' Donuts. After Winokur broke his partnership with Rosenberg, he went on to create Mister Donut with his son-in-law, David Slater that same year, with stores in most of North America. The Mister Donut business became so popular that Winokur and Slater decided to go into franchising. As a result, Mister Donut began a rapid expansion that resulted in the opening of 275 stores in the U.S. and Canada. In 1970, Minneapolis-based International Multifoods Corporation, one of the world's largest and most successful food companies, acquired Mister Donut and its franchising concept from Winokur. The first Mister Donut outlet in Japan opened in Minoh, Osaka in 1971. Also in the same year, a Mister Donut training center was constructed in Japan. In 1973, the French cruller became available in Japanese stores. In 1978, brothers Sutthichai and Sutthikiat Chirathiwat, on behalf of Thai Franchise Co., Ltd, opened the first Mister Donut store in Siam Square, Bangkok. The two would come to pioneer the donut market within Thailand. In 2003, Mister Donut in Thailand came under the management of CRG. Donut Thailand (Central Restaurants Group) which continues to manage the company in Thailand. In 1983, Duskin Co., Ltd. of Osaka, Japan, acquired the rights to franchise Mister Donut throughout Japan and Asia.
Computational neurogenetic modeling is concerned with the development of dynamic neuronal models for modeling brain functions with respect to genes and dynamic interactions between genes, on the cellular level (Computational Neurogenetic Modeling (CNGM) can also be used to model neural systems).
Excesses of stable 129Xe in meteorites have been shown to result from decay of "primordial" iodine-129 produced newly by the supernovas that created the dust and gas from which the Solar System formed. This isotope has long decayed and is thus referred to as "extinct". Historically, 129I was the first extinct radionuclide to be identified as present in the early Solar System. Its decay is the basis of the I-Xe iodine-xenon radiometric dating scheme, which covers the first 85 million years of Solar System evolution.
Significant breast development in transgender women begins within two to three months of the start of hormone therapy and continues for up to two years or more. Breast development seems to be better in transgender women who have a higher body mass index. This indicates that weight gain in the early phases of hormone therapy may be beneficial not only for fat distribution, but for breast development. Different estrogens, such as estradiol valerate, conjugated estrogens, and ethinylestradiol, appear to produce equivalent results in terms of breast sizes in transgender women. The sudden discontinuation of estrogen therapy has been associated with onset of galactorrhea (lactation). Breast, nipple, and areolar development varies considerably depending on genetics, nutrition, age of HRT initiation, and many other factors. Development can take a couple years to nearly a decade for some. However, many transgender women report there is often a "stall" in breast growth during transition, or significant breast asymmetry. Transgender women on HRT often experience less breast development than cisgender women (especially if started after young adulthood). For this reason, many seek breast augmentation. Transgender patients opting for breast reduction are rare. Shoulder width and the size of the rib cage also play a role in the perceivable size of the breasts; both are usually larger in transgender women, causing the breasts to appear proportionally smaller.
Sources: en.wikipedia.org
== Production == Approximately 1.5 million tons were produced in 1985, typically by the reaction of potassium chloride with sulfuric acid, analogous to the Mannheim process for producing sodium sulfate. The process involves intermediate formation of potassium bisulfate, an exothermic reaction that occurs at room temperature:
The term proofreading is used in genetics to refer to the error-correcting processes, first proposed by John Hopfield and Jacques Ninio, involved in DNA replication, immune system specificity, and enzyme-substrate recognition among many other processes that require enhanced specificity. The kinetic proofreading mechanisms of Hopfield and Ninio are non-equilibrium active processes that consume ATP to enhance specificity of various biochemical reactions. In bacteria, all three DNA polymerases (I, II and III) have the ability to proofread, using 3' → 5' exonuclease activity. When an incorrect base pair is recognized, DNA polymerase reverses its direction by one base pair of DNA and excises the mismatched base. Following base excision, the polymerase can re-insert the correct base and replication can continue. In eukaryotes, only the polymerases that deal with the elongation (delta and epsilon) have proofreading ability (3' → 5' exonuclease activity).Proofreading also occurs in mRNA translation for protein synthesis. In this case, one mechanism is the release of any incorrect aminoacyl-tRNA before peptide bond formation. The extent of proofreading in DNA replication determines the mutation rate, and is different in different species. For example, loss of proofreading due to mutations in the DNA polymerase epsilon gene results in a hyper-mutated genotype with >100 mutations per million bases of DNA in human colorectal cancers.
Staley's mother, Nancy McCallum, told The Seattle Times in 2007 that despite his isolation, he was never far from the love of his family and friends, who filled his answering machine and mailbox with messages and letters. "Just because he was isolated doesn't mean we didn't have sweet moments with him." McCallum has also claimed that she saw Staley on Thanksgiving of 2001, and again just around Valentine's Day of 2002, when he visited his sister's baby. This was the last time that McCallum saw her son. Sean Kinney has commented on Staley's final years and isolation period:
Sources: en.wikipedia.org
=== OSS-7: Dash7 open-source stack === The goal of the project is to provide a reference implementation of the DASH7 Alliance protocol. This implementation should focus on completeness, correctness and being easy to understand. Performance and code size are less important aspects. For clarity, a clear separation between the ISO layers is maintained in the code. The project is available on GitHub and is licensed under the Apache License, version 2.0.
== Mechanical properties == To ensure durability of PCs, mechanical properties are important to study. Elaborate efforts have been made for studying compressive brittleness of porous carbon materials. In 1999, Iizuka, et al. studied the mechanical properties of wood ceramics, a type of porous carbon material. Stable medium-density fiber was used as the base material of wood ceramics and phenol resin was impregnated into the board. Starting at 300 °C, Young's modulus and the compressive strength first decreased with increasing temperature, but at 500 °C the strength increases sharply until it reaches 800 °C and plateaus. The effects of temperature were due to microstructural changes in the resin during carbonization. Effects of impregnates phenol resin at 800 °C were also investigated. Results showed that Young's modulus increased with phenol resin impregnation (Figure 1). The maximum Young's modulus was 5 MPa and the maximum compressive strength was 80 MPa. Wall-bending mechanical test were also performed and it was found that cell wall is breakage was correlated to relative density on compressive strength and Young's modulus. Another type of compressive porous carbon consisting of cellulose and graphene aerogels was studied by Mi, et al. Modified cellulose/graphene aerogels (MCGA) was synthesized via bidirectional freeze drying and grafting of long carbon chains through chemical vapor deposition (Figure 2). The final product had a bulk density of 5.9 mg/cm3 and surface area of 47.3 m2/g with flexible cellulose nanofibril and stiff graphene components.
Insulin shock therapy or insulin coma therapy was a form of psychiatric treatment in which patients were repeatedly injected with large doses of insulin in order to produce daily comas over several weeks. It was introduced in 1927 by Austrian-American psychiatrist Manfred Sakel and used extensively in the 1940s and 1950s, mainly for schizophrenia, before falling out of favour and being replaced by neuroleptic drugs in the 1960s. It was one of a number of physical treatments introduced into psychiatry in the first four decades of the 20th century. These included the convulsive therapies (cardiazol/metrazol therapy and electroconvulsive therapy), deep sleep therapy, and psychosurgery. Insulin coma therapy and the convulsive therapies are collectively known as the shock therapies.
The relationship between sex steroids and SHBG in physiological and pathological conditions is complex, as various factors may influence the levels of plasma SHBG, affecting bioavailability of testosterone.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.